Inqovi Maintenance Therapy in Myeloid Neoplasms

Inclusion Criteria: * Pathologically confirmed diagnosis of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). * Subjects should have less than 5% myeloblasts on a bone marrow biopsy within 42 days prior to the start of conditioning. * Age ≥ 18 * Will undergo first allogeneic hematopoietic stem cell transplantation (HSCT) for their malignancy. * Transplantation will be performed with the use of reduced intensity conditioning (RIC). * HSCT Donor will be one of the following: * 5/6 or 6/6 (HLA-A, B, DR) matched related donor * 7/8 or 8/8 (HLA-A, B, DR, C) matched unrelated donor. Matching in the unrelated setting must be at the allele level. * Haploidentical related donor, defined as ≥ 3/6 (HLA-A, B, DR) matched * ≥ 4/6 (HLA-A, B, DR) umbilical cord blood (UCB). Matching in the UCB setting is at the antigen level. Recipients may receive either one or two UCB units. In the case of 2 UCB units, both units must have been at least 4/6 matched with the recipient. * ECOG performance status 0-2. * Participants must have normal organ and function as defined below: * AST (SGOT), ALT (SGPT) and Alkaline phosphatase \< 3x institutional upper limit of normal (ULN) * Total bilirubin \< 1.5 x ULN (with the exception of subjects with a history of Gilbert's syndrome) * Calculated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault formula) * LVEF must be equal to or greater than 50%, as measured by MUGA scan or echocardiogram * Female patients of childb…